Quantum BioPharma Momentum Score Surges As Investors Cheer Progress In MS Research

Quantum BioPharma Ltd. (NASDAQ:QNTM) saw its stock momentum score rise sharply from 16.74 to 84.2 on a week-over-week basis.

A momentum score is a metric that gauges the strength of a stock's trend by analyzing recent price movements and trading volume, helping indicate how strongly the stock is currently trending.

Quantum BioPharma MS Study Reaches Midpoint

The company announced that patient enrollment in the collaborative study has reached roughly 50%, alongside preliminary results from its novel PET imaging approach designed to directly measure demyelination in the brain.

Researchers using the [¹⁸F]3F4AP PET tracer reported strong imaging results in active MS lesions, suggesting potential for improved tracking of disease progression.

"We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma.

He added, "PET imaging with [¹⁸F]3F4AP has the potential to fundamentally change how we assess demyelination."

Dr. Pedro Brugarolas of Massachusetts General Hospital said the technique could provide a more direct way to measure myelin damage in the brain, an area that has long lacked precise tools in MS research.

Lucid-MS, Quantum's experimental therapy, is designed to protect myelin by targeting biological pathways involved in nerve damage.

The company said the imaging platform could help evaluate whether such treatments slow or reverse disease progression.

Benzinga's Edge Stock Rankings indicate a mixed price structure for Quantum BioPharma, with short- and medium-term trends turning positive while the long-term trend remains negative, according to the latest data.

Quantum BioPharma Fundraising Timing

President & CEO of Malone Wealth, Kevin Malone, posted on X that Quantum could have potentially raised nearly four times more capital if it had issued shares later in the year rather than earlier.

He argued that better timing aligned with market cycles, swaps, and failed-to-deliver (FTD) patterns might have improved fundraising outcomes.

Quantum Bio could have potentially raised almost 4X as much money if they would have sold shares today instead of the beginning of the year. I wish the company would have had someone advising them on yearly cycles, swaps, and FTD cycles. pic.twitter.com/RSaoWVaQVU

— Kevin Malone (@Malone_Wealth) May 26, 2026

Price Action

Quantum Biopharma closed at $7.64, up 8.37% on Wednesday, and rose 4.71% in pre-market trading on Thursday at the time of writing.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo courtesy: Shutterstock